Clinical trials: Mild and Moderate Alzheimer's Disease, active
Alzheimer Disease (AD)
Alzheimer's Disease Treated With Vagus Nerve Stimulation
The goal of this clinical trial is to evaluate the safety and efficacy of vagus nerve stimulation (VNS) for treating Alzheimer's disease (AD) in patients aged 50-80 years with mild cognitive impairment to moderate Alzheimer's…
- Trial name
- Advant (NCT06923007)
- Testing
- Vagus Nerve Stimulation
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 2 (NCT06976203)
- Testing
- KarXT, KarX-EC
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease
The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease
Alzheimer's disease (AD) is the leading cause of dementia, affecting millions worldwide. With its global prevalence steadily increasing, particularly in low- and middle-income countries, the demand for effective treatments has…
- Trial name
- NCT06840054
- Testing
- Sodium Pentaborate Pentahydrate
- Volunteers
- 30 people
- Sponsor
- Tabriz University of Medical Sciences
Alzheimer's Disease
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
This study is a Phase 2b/3 clinical trial of a new candidate drug (T3D-959) to treat patients with mild-to-moderate Alzheimer's.
- Trial name
- NCT06964230
- Testing
- T3D-959
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- T3D Therapeutics, Inc.
Dementia Moderate, Dementia, Mild
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
- Conditions
- Dementia Moderate, Dementia, Mild, Alzheimer Disease
- Trial name
- XanaMIA (NCT06125951)
- Testing
- Xanamem
- Where
- 34 sites in United States, Australia
- Volunteers
- 247 people
- Sponsor
- Actinogen Medical
Alzheimer Disease
Transcranial Near-infrared Light Therapy for Mild-Moderate Alzheimer's Disease (NIR4AD)
The goal of this study is to explore the efficacy and safety of Near-infrared light Photobiomodulation in patients with mild-moderate Alzheimer's disease(AD).
- Trial name
- NCT06160908
- Testing
- NirsCure
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Xuanwu Hospital, Beijing
Alzheimer Disease, Insomnia Disorder
Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease
DARIDOR-ALZ is a phase IV clinical trial designed to evaluate both the efficacy and safety of daridorexant, a selective dual orexin receptor antagonist that blocks the actions of the orexin neuropeptides at both orexin-1 and…
- Conditions
- Alzheimer Disease, Insomnia Disorder, Sleep
- Trial name
- DARIDOR-ALZ (NCT05924425)
- Testing
- Daridorexant 50 mg, Polysomnography, Neuropsychological assessment
- Where
- France
- Volunteers
- 62 people
- Sponsor
- University Hospital, Montpellier
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Alzheimer s Disease
Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)
This study is a multicenter, randomized, double-blind, sham-device-controlled clinical trial. A total of 320 patients with mild to moderate Alzheimer's disease (AD) are planned to be enrolled.
- Trial name
- NCT07262645
- Testing
- NirsCure 6000
- Where
- 23 sites in China
- Volunteers
- 320 people
- Sponsor
- Danyang Huichuang Medical Equipment Co., Ltd.
Alzheimer Disease
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.
- Trial name
- NCT06427668
- Testing
- SPG302
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Spinogenix
Alzheimer Disease, Cognitive Impairment
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study. Participants who complete the Hope Study (CA-0011) will be eligible to consent for screening to enroll…
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia, Mild
- Trial name
- NCT06245031
- Testing
- Sensory Stimulation System (GS120) - Active
- Where
- 53 sites in United States
- Volunteers
- 402 people
- Sponsor
- Cognito Therapeutics, Inc.
Mild to Moderate Alzheimer's Disease
The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease
This study is divided into two phases: a dose-escalation phase and an expansion cohort phase. The dose-escalation phase is a single-center study, while the expansion cohort phase is a multicenter, prospective, randomized…
- Trial name
- CB-EXOAD (NCT07457125)
- Testing
- Exosomes derived from umbilical cord mesenchymal stem cell for intranasal drop
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Xuanwu Hospital, Beijing
Osteoporosis
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
People with Alzheimer's disease are at an increased risk of bone fracture. Some studies have shown that those taking donepezil have a lower rate of bone fractures, but the reasons for this are unknown.
- Trial name
- NCT06041789
- Testing
- Donepezil, Memantine
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Duke University
Alzheimer&Amp;Amp;#39;s Disease, Alzheimer Disease
Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)
The goal of this clinical trial is to learn if using large-coil (or "deep") repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus and surrounding areas is feasible, tolerable, and potentially efficacious for…
- Conditions
- Alzheimer&Amp;Amp;#39;s Disease, Alzheimer Disease, Dementia Alzheimer Type, Mild Alzheimer&Amp;Amp;#39;s Disease
- Trial name
- PROMIS-AD (NCT06597942)
- Testing
- TMS
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of California, Los Angeles
Alzheimers Disease
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to…
- Trial name
- NCT04639050
- Testing
- RO7126209
- Where
- 37 sites in United States, Australia and 7 more
- Volunteers
- 241 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 1 (NCT06976216)
- Testing
- KarXT, KarX-EC
- Where
- 119 sites in United States, Argentina and 17 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Dementia
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
This study is a multicenter, randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group clinical trial.
- Trial name
- NCT07066826
- Testing
- Huperzine A Controlled-Release Tablets, Donepezil hydrochloride tablets
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Wanbangde Pharmaceutical Group Co., LTD
Alzheimer Disease
Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, global function, activities of daily living, resource utilisation, safety, and tolerability, in participants with mild to…
- Trial name
- ALTER-AD (NCT05809908)
- Testing
- Tricaprilin
- Volunteers
- 535 people
- Sponsor
- Cerecin
Alzheimer's Disease, Blood Brain Barrier
Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease
A single-center, single-arm, prospective, open-label, pilot clinical trial to evaluate the safety and efficacy of the Focused ultrasound stimulator system (NMS-01) for transient Blood-Brain Barrier (BBB) opening in patients with…
- Trial name
- NMSBBBOYUSH01 (NCT07869238)
- Testing
- NMS-01
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Neumous Inc.
Alzheimer's Disease Dementia
Alzheimer's Disease THErapy With NEuroaid II
ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects…
- Trial name
- ATHENE II (NCT07191028)
- Testing
- MLC 901
- Where
- Singapore
- Volunteers
- 350 people
- Sponsor
- Moleac Pte Ltd.